2.695

3.07% 0.085

Geovax Labs Inc (GOVX)

Overview News Price History Financials Discussions Forecast Stock Split

Geovax Labs Inc stock is traded at $2.695, with a volume of 288.12K. It is up +3.07% in the last 24 hours and up +20.09% over the past month. Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Previous Close:

$2.61

Open:

$2.62

24h Volume:

288.12K

Relative Volume:

0.11

Market Cap:

$23.02M

Revenue:

$356.60K

Net Income/Loss:

$-25.97M

P/E Ratio:

-3.6204

EPS:

-0.7444

Net Cash Flow:

$-25.22M

1W Performance:

+3.07%

1M Performance:

+20.09%

6M Performance:

+67.08%

1Y Performance:

-65.51%

1-Day Range:

$2.59

$2.74

1-Week Range:

$2.37

$3.12

52-Week Range:

$1.0901

$11.18

Geovax Labs Inc Stock (GOVX) Company Profile

Name

Geovax Labs Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

678-384-7220

Address

1900 LAKE PARK DRIVE, SMYRNA

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

GOVX's Discussions on Twitter

Compare GOVX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOVX	2.70	23.02M	356.60K	-25.97M	-25.22M	-0.7444
VRTX	447.28	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	744.21	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.30	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.36	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.93	24.49B	3.30B	-501.07M	1.03B	11.54

Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-16-24	Initiated	ROTH MKM	Buy
Nov-19-20	Initiated	Maxim Group	Buy

Geovax Labs Inc Stock (GOVX) Latest News

Nov 20, 2024

Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN

Nov 20, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire

Nov 20, 2024

Nov 19, 2024

GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia

Nov 19, 2024

GeoVax regains compliance with Nasdaq listing standards - Investing.com India

Nov 19, 2024

GeoVax reports progress in CLL vaccine booster trial - Investing.com India

Nov 19, 2024

GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada

Nov 19, 2024

GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks

Nov 19, 2024

GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan

Nov 19, 2024

Nov 16, 2024

Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World

Nov 16, 2024

Nov 15, 2024

Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia

Nov 15, 2024

Nov 14, 2024

Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $12.67 - Defense World

Nov 14, 2024

Nov 13, 2024

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call Transcript - MSN

Nov 13, 2024

Earnings call: GeoVax reports progress in vaccine trials, financial updates - Investing.com

Nov 13, 2024

U.S. Stock market top losers: Gaucho Group Holdings sees decline of 55.06% while GeoVax Labs looses 23.53% in early trading - Business Upturn

Nov 13, 2024

Alliance Global Partners Initiates Coverage on GeoVax Labs (NASDAQ:GOVX) - Defense World

Nov 13, 2024